Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma
- 1 June 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 179 (6) , 2096-2102
Abstract
We reviewed the contemporary literature on molecular biomarkers in renal cell carcinoma and their prognostic significance. Articles published during 1981 to 2007 in English on renal cell carcinoma were surveyed using the MEDLINE/PubMed database. The subject headings included were genetics, biomarkers, prognosis and risk models of renal cell carcinoma. We present a synthesis of currently known renal cell carcinoma biomarkers at various stages of development and their clinical significance, and prognostic nomograms incorporating biomarkers. The beneficiary role of biomarkers in renal cell carcinoma is challenged by the relatively low prevalence of the disease. Even if a biomarker for renal cell carcinoma had 100% sensitivity and 99.4% specificity, the positive predictive value of the marker in men older than 65 years would be only 10%. Several biomarkers are being investigated in renal cell carcinoma, of which many relate to pathogenic molecular changes that are currently therapeutic targets. Carbonic anhydrase IX is a von Hippel-Lindau mediated enzyme that is expressed in most renal cell carcinoma cases. High (greater than 85%) expression of this marker indicates favorable prognosis and may predict the response to interleukin-2 therapy. B7-H1 expression in renal cell carcinoma cells/lymphocytes may indicate worse survival, possibly through impaired host antitumor immunity. Prognostic nomograms incorporating clinical variables and molecular markers to refine the prediction of treatment outcomes are in active development and await prospective clinical validation. Several renal cell carcinoma molecular markers appear promising to refine the prognosis and prediction of localized, advanced or metastatic renal cell carcinoma. Currently carbonic anhydrase IX is the best studied and promising marker. Prospective, multicenter clinical validation aimed at the practical clinical usefulness of renal cell carcinoma biomarkers is warranted.Keywords
This publication has 29 references indexed in Scilit:
- Current status and future directions of molecular markers in renal cell carcinomaCurrent Opinion in Urology, 2006
- Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinomaLaboratory Investigation, 2005
- Biochemical and molecular markers in renal cell carcinoma: an update and future prospectsBiomarkers, 2005
- p21 WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivoJournal of Cancer Research and Clinical Oncology, 2003
- Prognostic Factors of Renal Cell CarcinomaJournal of Urology, 2003
- Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet‐activating factor synthesisInternational Journal of Cancer, 2002
- Erythropoietin stimulates proliferation of human renal carcinoma cellsKidney International, 2000
- MN/CA9 gene expression as a potential biomarker in renal cell carcinomaBJU International, 1999
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Basic isoferritin and hypercalcaemia in renal cell carcinomaJournal of Clinical Pathology, 1982